Literature DB >> 16847442

Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor.

Mark R Dowling1, Steven J Charlton.   

Abstract

Slow receptor dissociation kinetics has been implicated in the long clinical duration of action of the muscarinic receptor antagonist tiotropium. However, despite the potential benefits of new drugs with slow dissociation kinetics, the rate parameters of new compounds are seldom measured due to technical difficulties and financial implications associated with radiolabeling multiple ligands. Here we describe the development and optimisation of a medium throughput assay which is capable of measuring the kinetic parameters of novel, unlabelled compounds. Radioligand binding studies were performed with membranes derived from CHO cells recombinantly expressing the human M(3) muscarinic receptor.Initial characterisation of the radioligand [(3)H]-NMS yielded on and off rates of 4.1+/-0.2 x 10(8) M(-1) min(-1) and 0.015+/-0.0005 min(-1), respectively. The specific binding of [(3)H]-NMS was measured over time in the presence and absence of several concentrations of unlabelled competitor compounds. These data were analysed using a competition kinetic model to provide on and off rates for the unlabelled competitor. Comparison of the kinetically derived Kd (k(off)/k(on)) with K(i) values generated at equilibrium showed an excellent correlation (r(2)=0.99), providing good validation of the method. The on and off rates were also used in theoretical computer simulations to successfully predict the effect of incubation time on apparent IC(50) values. This study demonstrates that a medium-throughput competition kinetic binding assay can be used to determine accurate on and off rates of unlabelled compounds, providing the opportunity to optimise for kinetic parameters early in the drug discovery process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847442      PMCID: PMC1751918          DOI: 10.1038/sj.bjp.0706819

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

Review 1.  Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease.

Authors:  B Disse; G A Speck; K L Rominger; T J Witek; R Hammer
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

2.  Quantitation of mRNAs for M(1) to M(5) subtypes of muscarinic receptors in rat heart and brain cortex.

Authors:  Alena Krejcí; Stanislav Tucek
Journal:  Mol Pharmacol       Date:  2002-06       Impact factor: 4.436

3.  The rate of equilibration in a competitive n drug system and the auto-inhibitory equations of enzyme kinetics: some properties of simple models for passive sensitization.

Authors:  D Colquhoun
Journal:  Proc R Soc Lond B Biol Sci       Date:  1968-06-11

4.  The kinetics of competitive radioligand binding predicted by the law of mass action.

Authors:  H J Motulsky; L C Mahan
Journal:  Mol Pharmacol       Date:  1984-01       Impact factor: 4.436

5.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.

Authors:  W Vincken; J A van Noord; A P M Greefhorst; Th A Bantje; S Kesten; L Korducki; P J G Cornelissen
Journal:  Eur Respir J       Date:  2002-02       Impact factor: 16.671

6.  Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping.

Authors:  E B Haddad; J C Mak; P J Barnes
Journal:  Mol Pharmacol       Date:  1994-05       Impact factor: 4.436

7.  Muscarinic receptor binding characteristics of a human neuroblastoma SK-N-SH and its clones SH-SY5Y and SH-EP1.

Authors:  D G Lambert; A S Ghataorre; S R Nahorski
Journal:  Eur J Pharmacol       Date:  1989-06-08       Impact factor: 4.432

8.  (-)-S-[3H]CGP-12177 and its use to determine the rate constants of unlabeled beta-adrenergic antagonists.

Authors:  H Affolter; C Hertel; K Jaeggi; M Portenier; M Staehelin
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

9.  Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways.

Authors:  T Takahashi; M G Belvisi; H Patel; J K Ward; S Tadjkarimi; M H Yacoub; P J Barnes
Journal:  Am J Respir Crit Care Med       Date:  1994-12       Impact factor: 21.405

10.  Kinetic analysis of the interactions of agonists and antagonists with beta adrenergic receptors.

Authors:  M L Contreras; B B Wolfe; P B Molinoff
Journal:  J Pharmacol Exp Ther       Date:  1986-10       Impact factor: 4.030

View more
  32 in total

1.  Functional efficacy of adenosine A₂A receptor agonists is positively correlated to their receptor residence time.

Authors:  Dong Guo; Thea Mulder-Krieger; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 2.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.

Authors:  A Packeu; M Wennerberg; A Balendran; G Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

4.  Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5.

Authors:  Angela Arsova; Thor C Møller; Line Vedel; Jakob Lerche Hansen; Simon R Foster; Karen J Gregory; Hans Bräuner-Osborne
Journal:  Mol Pharmacol       Date:  2020-05-01       Impact factor: 4.436

5.  Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists.

Authors:  David A Sykes; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 6.  Ligand binding assays at equilibrium: validation and interpretation.

Authors:  Edward C Hulme; Mike A Trevethick
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

7.  Second M3 muscarinic receptor binding site contributes to bronchoprotection by tiotropium.

Authors:  Loes E M Kistemaker; Carolina R S Elzinga; Christofer S Tautermann; Michael P Pieper; Daniel Seeliger; Suraya Alikhil; Martina Schmidt; Herman Meurs; Reinoud Gosens
Journal:  Br J Pharmacol       Date:  2019-07-02       Impact factor: 8.739

8.  Kv 11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical Kv 11.1 (hERG) inhibitors.

Authors:  Z Yu; A P IJzerman; L H Heitman
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

9.  Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo.

Authors:  Simeon J Ramsey; Neil J Attkins; Rebecca Fish; Piet H van der Graaf
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

10.  Characterization of 12 GnRH peptide agonists - a kinetic perspective.

Authors:  Indira Nederpelt; Victoria Georgi; Felix Schiele; Katrin Nowak-Reppel; Amaury E Fernández-Montalván; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2015-11-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.